Managing Labor with each Contraction

PreTel Solutions



PreTel’s area sensor uterine electromyography (uEMG) monitoring solves the inability of existing technology to accurately identify independent contraction activity of individual regions of the uterus. Identification of this regional activity allows for improved care in the preterm labor patient, managing the progress of labor at time of delivery, and safety to the administration of induction therapy.

These improvements will avoid unnecessary C-Section deliveries, post-delivery maternal hemorrhage, and expensive neonatal intensive care nursery stays.

PreTel Monitoring Systems

PreTel pregnancy monitoring systems integrate the reporting of fetal heart rate (FHR), maternal heart rate (MHR), contraction activity and individual region activity into a portable patient wearable device. System solutions include interface to existing hospital central monitoring hardware and cloud access for home monitoring applications.

The PreTel pregnancy monitoring system improves both maternal and neonatal outcomes in the labor and delivery department, across hospital systems and throughout integrated health care networks.

PreTel Area Sensors

Pregnancy monitoring impacts 3.7 Million births (US) improving both maternal and neonatal outcomes.


Regional uterine monitoring results in:

Supports preterm labor management

Evaluates therapy response

Accurate antepartum assessment

Differentiates false from true labor contractions

Labor progress information

Avoids unnecessary induction or C-section

Safely conducts induction therapy

Avoids tachysystole

PreTel area sensors provide new information

Measure regional uterine synchronization

Indicates type of contraction

Evaluates progress of labor

Increase/decrease of synchronization

Additional Observations & Measurements

Evaluation of oxytocin induction during contraction rest periods

Technology Advantages

Wearable Area Sensor technology provides the determination of the amount of individual regions of the uterus that make up each contraction. This unique uterine EMG technique is combined with fetal and maternal ECG monitoring in the PreTel Juno Pregnancy Monitoring System. The PreTel Juno Pregnancy Monitoring Systems not commercially available for sale.


Advantages over traditional
monitoring systems:

  • Wearable Sensor Array
    Avoids the need for sensor repositioning by L&D staff
  • Bluetooth Data Transmission
    Allows patient mobility by eliminating sensor cords
  • Integrates Uterine Activity, Fetal and Maternal Heart Rate Monitoring
    Eliminate need for multiple monitoring devices

Advantages over standard
EMG monitoring systems:

  • Directional Regional Uterine Activity Sensor
    Identifies individual regions of contraction activity
  • Proprietary Regional Activity Assessment
    Determines regional coordination and synchronization

PreTel Clinical Management Advantages:

  • Reporting of Regional Progress to Coordination and Synchronization
  • Evaluates preterm labor therapy response
  • Improves antepartum assessment of true and false labor contractions
  • Identifies progress and lack of labor progress to delivery
  • Identifies precursor to tachysystole during induction delivery


News

PreTeL Selected as Finalist for RESI Conference

Chattanooga, TN —January 10, 2025 - PreTeL, Inc., arapidly emerging private AI powered Femtech company focusing on improving the lives of expectant mothers and women in labor, announced today that it will be presenting the initial clinical study results of their Preterm Labor Status Monitor at the Reinventing Early Stage Investing (RESI) JPM Innovator’s Pitch Challenge on January 14th during the Medical Device session from 2:00 -3:00.

“Our results out of the ongoing NIH funded clinical studies at Duke University, University of Rochester Medical Center and LSU Health Sciences Center indicate that PreTeL can accurately predict those babies who will be delivered preterm within the next 7 days – indicating when antenatal corticosteroids can be administered to significantly reduce the incidence of death, respiratory distress syndrome and other debilitating outcomes,” said PreTeL CEO Marc Finch, who will be presenting in the at the conference. “Providing treatments to these pregnancies will improve the health of hundreds of thousands of our children annually.”

“The Society for Maternal-Fetal Medicine recently stated that there is no validated method to estimate the probability of preterm birth within 7 days, citing a critical need for improvement that PreTel plans to provide,” said PreTeL Chairman Mark A Samuels. “In addition, PreTel’s pipeline includes new technology for objectively measuring the effects of Pitocin that could help physicians make better decisions during the induction of labor”. In some cases, suboptimal administration of Pitocin can lead to very significant fetal distress and/or mortality. Pitocin is involved in a larger number of labor and delivery malpractice claims.

About PreTel

PreTeL, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and AI enabled intelligent analysis for the large maternalfetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com

PreTeL Selected as Finalist for RESI Conference

Chattanooga, TN —September 4, 2024 - PreTeL, Inc., a rapidly emerging private AI enable Femtech company focusing on improving the lives of expectant mothers and women in labor, announced today that it has been selected to present at the Reinventing Early Stage Investing (RESI) Boston Innovator’s Pitch Challenge at their upcoming conference on September 25th.

“Early results out of the ongoing NIH funded clinical studies at Duke University and University of Rochester Medical Center indicate that PreTeL can significantly improve preterm labor prediction,” said PreTeL CEO Marc Finch, who will be presenting in the Digital Health and AI section at the conference. “We expect that we could begin commercialization in 2-3 years.”

“PreTeL has the potential to improve the lives of mother and their babies everywhere by doing a much better job of helping physicians predict the onset of preterm labor and potentially help adjust Pitocin (Oxytocin) dosage once labor has started,” said PreTeL Chairman Mark A Samuels. “Current predictions of preterm labor are inadequate and lead to significant increases in infant morbidity and healthcare costs”. Improved evaluation leads to better outcomes through the timely and appropriate treatment to reduce preterm birth complications. In addition, improper dosage of Pitocin can lead to very significant fetal distress and/or mortality. Pitocin is involved in about 50% of all labor and delivery malpractice claims.

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com

PreTeL Announces Grant Funding that will expand clinical Indications for our Regional Synchronization Technology
The grant will be used to advance our clinical data to obtain an indication for labor Induction dosing guidance with our synchronization monitor.

Chattanooga, TN —September 19, 2023 - PreTel has announced a Launch Tennessee “matching grant” award of $300k to their NIH SBIR grant “Labor Status Monitor for Diagnosing True Versus False Labor in Preterm Patients”. The grant will allow development into expanded clinical solutions in the use of regional synchronization in addition to preterm labor.

“This grant is another example the recognition of PreTeL’s achievement of clinical proof on concept of all three of our solutions and how they are very valuable to hospital provider, insurance companies and especially physicians and patients themselves,” stated Marc Finch, CEO. “PreTeL’s technology is designed to significantly improve the ability of healthcare professionals to quickly and accurately diagnose the status of labor, providing the first bedside dosing guidance system for Pitocin administration and expanding the use and accuracy of fetal monitoring - all significantly improving outcomes and reducing costs.”

Roger Young, MD, PhD, founder of PreTeL, said, “This grant represents continuing support from Launch Tennessee that will assist us in completing our mission – to translate newly discovered science and technology into medical devices that transform the practice of obstetrics. A new discovery, found using our regional synchronization technology, now allows us to extend our scope beyond our initial focus on preterm labor patients. Our new device provides objective dosing guidance for Pitocin, which is used to induce labor and facilitate normal delivery. Each device represents a major advance in the management of a long-standing problem in obstetrics, and each will improve the health and safety of mothers and babies.”

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com

About Launch Tennessee

Launch Tennessee (LaunchTN) is a public-private partnership uniquely positioned to cultivate and support collaboration among founders, investors, the private sector, institutions, and government. We support Tennessee’s entrepreneurial ecosystem by coordinating resources, advancing capital access, and empowering our Network Partners and multiple stakeholders throughout the state to activate inclusive and sustainable economic growth in Tennessee.

PreTel Announces First Patients Enrolled in Labor Status Monitor Study
This Study will Diagnose True Versus False Labor in Preterm Patients.

Chattanooga, TN —August 29, 2023 - PreTel has announced the first patients have been enrolled in their NIH SBIR grant supported study “Labor Status Monitor for Diagnosing True Versus False Labor in Preterm Patients”.

“This is PreTel’s first study to convert our proprietary technology of uterine myography signal detection into intelligent analysis for preterm labor diagnosis and maternal and fetal safety during labor and delivery into a bedside monitoring clinical solution,” stated Marc Finch, CEO. “40% of all women in the United States experience false labor at a very high financial cost to the system and an emotional cost for the patient. Our wearable “Area Sensor” platform is designed to quickly and accurately diagnose false labor allowing healthcare providers to manage patient care at a significantly reduced cost.”

The first patient was enrolled at the University of Rochester where co-PI’s Dr. Neil Seligman, MD, Associate Professor and Ponnila Marinescu, MD, Associate Professor commented, “We are very excited to continue our research using the PreTel technology of pregnancy status monitoring in the preterm population. We have worked together and published on the proof-of-concept studies and are now thrilled to investigate its bedside patient care solutions.”

Roger Young, MD, PhD, founder of PreTel, said, “This is the culmination of my career’s work in both understanding the physiology of the pregnant uterus and the development of a novel skin-wearable sensor to detect the regional functioning of the uterus as it transitions to labor. I have developed this technology to improve the health and safety of mothers and babies during pregnancy and labor using its advanced technology platform aimed at predicting labor, monitoring the progress of labor and adjusting Pitocin drug delivery,”

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com

PreTeL, Inc. to Present at the 2022 Society for Maternal Fetal Medicine 42nd Annual Pregnancy Meeting

Chattanooga, TN —December 10, 2021 - PreTeL, Inc., a rapidly emerging Femtech company focusing on improving the lives of expectant mothers and women in labor announced today that its abstract “EMG provides insights into preterm birth: Mid-trimester cervical shortening is associated with abnormal myometrial activation” will be presented during the initial Plenary Session at the Society of Maternal Fetal Medicine’s (SMFM) 42nd Annual Pregnancy Meeting to be held January 1- February 5, 2022 in Orlando, Florida. The PreTeL Labor Status Monitor utilizes a proprietary “Uterine Area Sensor” designed specifically to record local electromyographic (EMG) activities produced by small regions of the pregnant uterus.

Dr. Roger Young, Chief Medical Officer at PreTeL says, “Mid-trimester cervical shortening is an excellent screening tool that can identify patients who are at risk for delivering preterm. However, being able to classify patients as high-risk raises three crucial questions: Who needs intervention? What intervention is most appropriate? When should the intervention be performed? The EMG data we present are physiological changes that complement the anatomic findings, and define a pathway to answering at least one, and perhaps all three questions.”

Marc Finch, CEO added “Our abstract was judged as 3rd best worth of a plenary presentation, indicating maternal fetal medicine specialists desire to learn more about our technology and to support its further development. Our goal is to reduce the likelihood of a preterm birth for those at risk for preterm delivery, such as those with short cervix diagnosed in early pregnancy. While the expenses associated with a preterm birth are ten to fifty times those of a term delivery, permanent disabilities such as cerebral palsy, chronic respiratory disorders, cognitive delay and visual and hearing disorder occur much more often in preterm babies.”

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com

PreTel, Inc. to Present at the 2021 Society for Maternal Fetal Medicine Annual Meeting

Chattanooga, TN —January 26, 2021 - PreTel, Inc., a rapidly emerging Femtech company focusing on improving the lives of expectant mothers and women in labor. announced today that data from its unique preterm labor test will be presented at the Society of Maternal Fetal Medicine’s (SMFM) annual meeting to be held January 25-30. The PreTel test utilizes a proprietary “Uterine Area Sensor” technology for electromyography (EMG) signal detection and isolation for preterm labor diagnosis and management.

“By using our sensors and analysis, we are able to distinguish true from false labor with high specificity. We anticipate this diagnostic tool will dramatically improve the management of preterm and term women who present in threatened labor,” added Dr. Roger Young, Chief Medical Office at PreTel. “Pretel’s approach is revolutionary, since for the first time, Uterine Area Sensors are used to isolate the EMG signals from specific locations on the uterus. Through a proprietary analysis, the local uterine bioactivities are then processed to detect both the strong contractions of true labor and novel signals that indicate false labor.”

Marc Finch, CEO added “We are developing this technology to provide physicians the opportunity to rapidly intervene when preterm labor is diagnosed. Our goal is to reduce the likelihood of a preterm birth for those in true labor and avoid unnecessary hospitalization for those in false labor. While the expenses associated with a preterm birth are ten to fifty times those of a term delivery, permanent disabilities such as cerebral palsy, chronic respiratory disorders, cognitive delay and visual and hearing disorder occur much more often in preterm babies.”

The poster presentation “Distinguishing true from false labor with a novel labor test” (#553) at the SMFM annual meeting will occur at 8:30 am EDT on Friday, January 29th for all attendees to this year’s virtual meeting. (It can be view on www.pretelhealth.com immediately after the presentation.)

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com

PreTel Selected to Present at ADVANSE Life Sciences Conference

Chattanooga, TN —October 15, 2021 - PreTel, Inc., a rapidly emerging private Femtech company focusing on improving the lives of expectant mothers and women in labor, has been selected to present to investor attendees at the ADVANSE Life Sciences Conference highlighting advances in Biopharma, Medtech, Diagnostic and Digital Health.

PreTeL will present its patented uterine EMG technology that through digital signal analytics determines true from false labor in high-risk preterm patients. Founder Roger Young, MD, PhD, commented “Our clinical studies show that improving ECG/EMG signal acquisition and using advanced analytics translates into new solutions for pregnancy management that fulfill long-standing clinical needs. We envision a trio of solutions such as preterm labor diagnosis, labor induction oxytocin (Pitocin) dosing support, and preterm fetal monitoring.”

Marc Finch, CEO, indicated “There are over 1.3 million trips to the ER ever year for preterm contractions, in which diagnostic accuracy is only 30%. Incorrect diagnosis result in unnecessary hospitalization or failure to provide therapeutic steroid therapy critical to the health of the preterm infant. Our Labor Status Monitor will improve accuracy to over 80% greatly improving neonatal health. PreTeL’s platform of monitors will expand the scope of pregnancy monitoring of the 3.5 million pregnancies every year by providing new methods of diagnosis and therapy dosing support. Our goals are to simultaneously reduce human suffering of mother and baby and reduce health care costs of pregnancy, ultimately becoming the leading provider of pregnancy monitoring”

Marc Finch, will present PreTel to ADVANSE investor attendees Thursday October 28th.

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com



The pretel Team

We are a team of professionals, dedicated to improving the health of women and babies by expanding their options with innovative medical devices that provide significant clinical impact.

Roger Young, MD

Founder
READ BIO

Marc Finch

CEO
READ BIO

Dave Adair, MD

Board Member
READ BIO

Blake Patton

Board Member
READ BIO

PreTeL Conflict of Interest Policy

A conflict of interest is a situation in which an investigator’s outside financial interests or obligations (real or perceived) have the potential to bias a research project or cause harm to human subjects participating in a research project.


The Public Health Service (PHS) and the National Institutes of Health (NIH) require PreTeL to disclose significant financial interests (SFI) by investigators who participate in funded research either directly or indirectly or by subaward, as well as the investigator’s close family members. PreTeL’s policy is to ensure compliance with federal regulation described at 42 CFR Part 50, Subpart F.

To view PreTeL’s financial Conflict of Interest Policy, please click here.